In the News: February 23-March 1
Sg2 is dedicated to helping our clients interpret the latest news and trends in health care. Below you’ll find our analysis of this week’s key industry headlines, along with links to related Sg2 resources.
Consumer Information on Physician Quality Remains Limited
Even though the majority of patients value online physician reviews, these reviews may be limited or difficult to access, according to a new JAMA study. The study found significant gaps in information on commercial websites that rate physicians—with no online information available for one-third of the physicians sampled—as well as limited search functions that did not allow patients to search for physicians by sex or language spoken.
Sg2 believes that the demand for user-friendly, convenient services requires a new perspective in strategic planning: a consumer lens. Read the Sg2 report Reinventing the Patient Journey: A Consumerism Update and Outlook to learn more about the needs, pain points and evolution of the consumer ecosystem.
Leaked ACA Repeal Plan Draft Reveals More Changes
Last Friday, Politico posted a leaked draft of the House Republican bill online that includes specifics and key numbers missing from the recent policy brief announced by HHS Secretary Tom Price and House Speaker Paul Ryan. Notably, the leaked bill would phase out Medicaid expansion by 2020; transition federal Medicaid funding to per-capita grants; change requirements for health plans’ coverage of health care services; and expand health plans’ ability to charge higher premiums for older beneficiaries.
However, the leaked draft is dated February 10 and is unlikely to be submitted in its current form. Given the current level of uncertainty, Sg2 thinks this will be a pivotal year for health care leaders to challenge themselves and their organizations to make better decisions. To learn more, read the January 2017 Sg2 Letter.
CRISPR Patent Lawsuits Continue
Two US groups have been vying for patent rights for CRISPR (pronounced crisp-er) technology. CRISPR-based therapeutics can potentially cure genetic diseases such as sickle cell anemia, cystic fibrosis, muscular dystrophy and blindness, as well as multiple liver diseases. On February 15, 2017, the Patent Trial and Appeals Board judge ruled that both groups own patent rights, which will likely result in a cascade of additional appeals and lawsuits.
Deciphering which innovations won’t fizzle out or morph into red line items is tough. Read the Sg2 report The Next-Generation Technology Platform to explore noteworthy technologies and understand key applications, core market players and example innovators from outside the health care space.